Genmab A/S Sponsored ADR (GMAB)
Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff
Genmab A/S is leveraging its royalty-centric model and new ADCs like Epkinly to offset upcoming Darzalex patent expiry risks. Epkinly's strong Phase 3 data in follicular lymphoma positions GMAB for blockbuster potential and validates its co-promotion strategy with AbbVie. Despite a recent rally, GMAB remains undervalued versus peers, with robust profitability, cash flow, and a discounted forward P/E ratio.
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade
The mean of analysts' price targets for Genmab (GMAB) points to a 33.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript
Genmab A/S (GMAB) Q2 2025 Earnings Conference Call August 7, 2025 12:00 PM ET Company Participants Anthony Pagano - Executive VP & CFO Brad Bailey - Corporate Participant Jan G.J. van de Winkel - Co-Founder, President & CEO Judith V.
GMAB vs. ACAD: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now?
Genmab (GMAB) Upgraded to Strong Buy: Here's Why
Genmab (GMAB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?
The mean of analysts' price targets for Genmab (GMAB) points to a 40% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
Genmab A/S is a high-margin, royalty-driven biotech with a robust pipeline and strong partnerships, notably with J&J, AbbVie, and Pfizer. Darzalex remains the key revenue driver, but patent protection and new indications should sustain growth for at least four more years. The company boasts a rock-solid balance sheet, undervalued metrics (low PE, PEG, high FCF yield), and active share buybacks.
Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology
Genmab has promising proprietary antibody platforms and partnerships that have helped it transition from licensor to commercial-stage biotech. Their robust royalty stream from Darzalex and Kesimpta funds R&D, while net product sales of epcoritamab and Tivdak are quickly growing as well. Their late-stage pipeline includes epcoritamab label expansions, Rina-S in ovarian cancer, and Acsunilimab in NSCLC. Each of these candidates targets large TAMs.
GMAB or RGEN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Genmab A/S Sponsored ADR (GMAB) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?
Should Value Investors Buy Genmab (GMAB) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Genmab's Outlook Beyond Darzalex's Patent Cliff
Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a cautious approach. The company's robust late-stage pipeline could offset DARZALEX revenue loss with new product launches expected between 2027-2031. Genmab's strong balance sheet with $2.9 billion in cash and no long-term debt provides financial flexibility for R&D and strategic acquisitions.
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S' GMAB Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy.
